Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study

被引:17
作者
Abdel-Rahman, Omar [1 ]
机构
[1] Ain Shams Univ, Clin Oncol Dept, Fac Med, Cairo, Egypt
关键词
Non-Hodgkin lymphoma; Renal cancer; Second cancer; Second malignant neoplasm; Thyroid cancer; RENAL-CELL CARCINOMA; THYROID-CANCER; MUTATIONS; SURVIVORS; GENE; METAANALYSIS; FAMILY;
D O I
10.1016/j.clgc.2017.02.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Surveillance, Epidemiology, and End Results (SEER)-9 database (1973-2013) was queried using the SEER*Stat program. A total of 10,145 kidney cancers were observed. Many common cancers are associated with an increased risk of kidney cancer development. Background: Population-based data on the development of kidney cancer as a second malignant neoplasm following the diagnosis of other common malignancies are rare. This clinical scenario has been evaluated within the Surveillance, Epidemiology, and End Results (SEER) database. Materials and Methods: The SEER-9 database (1973-2013) was queried using the SEER*Stat program to determine the standardized incidence ratios (SIRs) of kidney cancer development following each one of 10 common invasive malignancies (colorectal, breast, prostate, lung, thyroid, corpus uteri, urinary bladder, kidney/renal pelvis, cutaneous melanoma, and non-Hodgkin lymphoma). The following data were collected for patients with a second renal cancer: age at diagnosis of the second renal cancer; gender, race, and histology of the second primary renal cancer; SEER historic stage of the second primary renal cancer; and method of diagnostic confirmation of the second primary cancer. Results: A total of 10,145 kidney cancers were observed. Elevated SIRs for kidney cancer were noted for all 10 evaluated malignancies in the initial 12 months after diagnosis. The SIRs remained elevated 12 to 59 months after diagnosis for all cancers except breast and prostate cancers. Increased risks persisted 60 to 119 months beyond diagnosis for renal cancer (SIR, 4.13), thyroid cancer (SIR, 2.30), and non-Hodgkin lymphoma (SIR, 1.40); and 120+ months for renal cancer (SIR, 3.60), thyroid cancer (SIR, 1.90), and non-Hodgkin lymphoma (SIR, 1.27). Increased kidney cancer risk after non-Hodgkin lymphoma was not related to radiation therapy. Papillary renal cell carcinoma has the highest SIRs for subsequent kidney cancers. Conclusion: Many common cancers are associated with an increased risk of kidney cancer development within the first 5 years after their diagnosis. Although this can be partly interpreted by increased rates of surveillance tests, radiotherapy effects, or genetic associations for some cancers, additional research is required to explain the persistently increased risk beyond 5 years associated with some cancers. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E747 / E754
页数:8
相关论文
共 21 条
[1]  
Abdel-Rahman O., CLIN GENITOURIN CANC
[2]   Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency [J].
Alam, NA ;
Rowan, AJ ;
Wortham, NC ;
Pollard, PJ ;
Mitchell, M ;
Tyrer, JP ;
Barclay, E ;
Calonje, E ;
Manek, S ;
Adams, SJ ;
Bowers, PW ;
Burrows, NP ;
Charles-Holmes, R ;
Cook, LJ ;
Daly, BM ;
Ford, GP ;
Fuller, LC ;
Hadfield-Jones, SE ;
Hardwick, N ;
Highet, AS ;
Keefe, M ;
MacDonald-Hull, SP ;
Potts, EDA ;
Crone, M ;
Wilkinson, S ;
Camacho-Martinez, F ;
Jablonska, S ;
Ratnavel, R ;
MacDonald, A ;
Mann, RJ ;
Grice, K ;
Guillet, G ;
Lewis-Jones, MS ;
McGrath, H ;
Seukeran, DC ;
Morrison, PJ ;
Fleming, S ;
Rahman, S ;
Kelsell, D ;
Leigh, I ;
Olpin, S ;
Tomlinson, IPM .
HUMAN MOLECULAR GENETICS, 2003, 12 (11) :1241-1252
[3]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[4]  
[Anonymous], GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
[5]   Racial and ethnic differences in risk of second primary cancers among breast cancer survivors [J].
Calip, Gregory S. ;
Law, Ernest H. ;
Ko, Naomi Y. .
BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) :687-696
[6]   Elevated Risks of Subsequent Primary Malignancies in Patients With Thyroid Cancer: A Nationwide, Population-Based Study in Korea [J].
Cho, Yoon Young ;
Lim, Jiwon ;
Oh, Chang-Mo ;
Ryu, Junsun ;
Jung, Kyu-Won ;
Chung, Jae Hoon ;
Won, Young-Joo ;
Kim, Sun Wook .
CANCER, 2015, 121 (02) :259-268
[7]   Hereditary papillary renal carcinoma type I [J].
Dharmawardana, PG ;
Giubellino, A ;
Bottaro, DP .
CURRENT MOLECULAR MEDICINE, 2004, 4 (08) :855-868
[8]   Risk of Second Primary Malignancies Among Cancer Survivors in the United States, 1992 Through 2008 [J].
Donin, Nicholas ;
Filson, Christopher ;
Drakaki, Alexandra ;
Tan, Hung-Jui ;
Castillo, Alex ;
Kwan, Lorna ;
Litwin, Mark ;
Chamie, Karim .
CANCER, 2016, 122 (19) :3075-3086
[9]   Obesity, Cholesterol, and Clear-Cell Renal Cell Carcinoma (RCC) [J].
Drabkin, Harry A. ;
Gemmill, Robert M. .
ADVANCES IN CANCER RESEARCH, VOL 107, 2010, 107 :39-56
[10]   The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study [J].
Guan, Xu ;
Jin, Yinghu ;
Chen, Yinggang ;
Jiang, Zheng ;
Liu, Zheng ;
Zhao, Zhixun ;
Yan, Peng ;
Wang, Guiyu ;
Wang, Xishan .
PLOS ONE, 2015, 10 (11)